Adynxx (Adynxx) Debt-to-Equity : -0.86 (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Debt-to-Equity?

Adynxx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $8.97 Mil. Adynxx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.52 Mil. Adynxx's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $-11.06 Mil. Adynxx's debt to equity for the quarter that ended in Sep. 2019 was -0.86.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Adynxx's Debt-to-Equity or its related term are showing as below:

ADYX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Adynxx Debt-to-Equity Historical Data

The historical data trend for Adynxx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Debt-to-Equity Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Debt-to-Equity

Get a 7-Day Free Trial

0.23

0.36

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Debt-to-Equity	Get a 7-Day Free Trial															-	-	0.14	-0.94	-0.86

Competitive Comparison of Adynxx's Debt-to-Equity

For the Biotechnology subindustry, Adynxx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Adynxx's Debt-to-Equity falls into.

Adynxx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Adynxx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	8.252
	=	0.00

Adynxx's Debt to Equity Ratio for the quarter that ended in Sep. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.965	+	0.519)	/	-11.062
	=	-0.86

Adynxx (OTCPK:ADYX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Adynxx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Adynxx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (Adynxx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Executives

Gregory J. Flesher	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning	officer: CHIEF MEDICAL OFFICER	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102